Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
Open Access
- 7 November 2022
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27 (12) , 1795-1804
Abstract
Background: Cluster of differentiation (CD) 73-targeted immunotherapy and CD73 inhibition may reduce adenosine production, which can augment the host and/or immunotherapy response to tumours. We aimed to assess the safety and tolerability, pharmacokinetics, and antitumour activity of oleclumab, an anti-CD73 monoclonal antibody, in adult Japanese patients with advanced solid malignancies resistant to standard therapy. Methods: In this phase I, single-centre, open-label study, patients received oleclumab 1500 mg (Cohort 1) or 3000 mg (Cohort 2) intravenously every 2 weeks. Results: In total, six patients were enrolled in the study (three in each cohort), and all six patients received the study treatment. The median patient age was 56.0 years and 4/6 were males. All patients (100%) reported adverse events (AEs) during the study; five (83.3%) patients reported AEs related to the study treatment. One (16.7%) patient reported a Grade 3 AE (neutrophil count decreased) that was not related to the study treatment. No AEs with an outcome of death were reported, and no patients reported AEs or serious AEs leading to oleclumab discontinuation/dose interruption. No dose-limiting toxicities were reported, and no patient discontinued due to an AE related to the study treatment. Oleclumab exposure increased dose proportionally. No patient achieved disease control at 8 weeks, and all six patients developed progressive disease. Conclusions: Oleclumab was well tolerated in adult Japanese patients with advanced solid malignancies and no unexpected safety concerns were raised; oleclumab exposure increased with dose. Future studies on combination therapy with other agents are warranted.Keywords
Funding Information
- AstraZeneca K.K.
This publication has 26 references indexed in Scilit:
- Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancerOncotarget, 2017
- Targeting CD73 in the tumor microenvironment with MEDI9447OncoImmunology, 2016
- Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of actionmAbs, 2016
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian CancerCancer Research, 2015
- Ecto-5′-nucleotidase expression is associated with the progression of renal cell carcinomaOncology Letters, 2015
- Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinomaOncotarget, 2014
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbsClinical Cancer Research, 2013
- Overexpression of CD73 in Prostate Cancer is Associated with Lymph Node MetastasisPathology and Oncology Research, 2013
- Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinomaWorld Journal of Gastroenterology, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009